Stockscreener 앱 받기
2.92
3.47%
-0.105
시간 외 거래:
2.92
전일 마감가:
$3.025
열려 있는:
$3.02
하루 거래량:
15,015
Relative Volume:
0.19
시가총액:
$92.09M
수익:
$709.00K
순이익/손실:
$-43.14M
주가수익비율:
-0.6432
EPS:
-4.54
순현금흐름:
$-20.35M
1주 성능:
-9.32%
1개월 성능:
+5.42%
6개월 성능:
+0.00%
1년 성능:
+9.77%
1일 변동 폭
$2.885
$3.105
1주일 범위
$2.87
$3.35
52주 변동 폭
$1.922
$4.75
OncoCyte Corporation Stock (OCX) Company Profile
명칭
OncoCyte Corporation
전화
510-775-0515
주소
1010 Atlantic Avenue, Suite 102, Alameda, CA
OCX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCX
OncoCyte Corporation
|
2.92 | 92.09M | 709.00K | -43.14M | -20.35M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 개시 | Lake Street | Buy |
| 2022-05-24 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-03-17 | 재개 | Needham | Buy |
| 2021-01-07 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 개시 | BTIG Research | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 재확인 | The Benchmark Company | Speculative Buy |
| 2020-07-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 개시 | Needham | Buy |
| 2019-02-13 | 개시 | Piper Jaffray | Overweight |
| 2019-01-29 | 업그레이드 | Janney | Neutral → Buy |
| 2018-12-19 | 재개 | Lake Street | Buy |
모두보기
OncoCyte Corporation 주식(OCX)의 최신 뉴스
Geode Capital Management LLC Has $326,000 Stock Position in OncoCyte Co. (NASDAQ:OCX) - Defense World
Oncocyte Provides Positive Update on Clinical Trial Progress | O - GuruFocus
Why Tesla Stock Hit the Brakes Today - The Globe and Mail
AP PHOTOS: US stocks sink after a weak report on the economy - The Globe and Mail
Oncocyte (OCX) Advances Towards Crucial Clinical Trial for Trans - GuruFocus
Oncocyte advances toward clinical trial for transplant test By Investing.com - Investing.com India
Oncocyte advances toward clinical trial for transplant test - Investing.com Australia
Oncocyte Provides Positive Update on Clinical Trial Progress - The Manila Times
Oncocyte Provides Positive Update on Clinical Trial Progress | OCX Stock News - GuruFocus
Oncocyte Provides Positive Update On Clinical Trial ProgresS - marketscreener.com
Leading US Transplant Centers Back Oncocyte's Revolutionary Rejection Test Clinical Trial - Stock Titan
OncoCyte (NASDAQ:OCX) Trading Down 3.1% – Here’s What Happened - Defense World
Oncocyte study links blood test to kidney rejection markers - Investing.com
Economic Uncertainty Weighs on PayPal - The Globe and Mail
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Val - GuruFocus
Oncocyte (OCX) Unveils Promising Data on Transplant Rejection Te - GuruFocus
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity | OCX Stock News - GuruFocus
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity - The Manila Times
Groundbreaking Study: Oncocyte's Transplant Test Shows Unprecedented 13-Year Effectiveness in Rejection Detection - Stock Titan
Trane Technologies (TT) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
Service International (SCI) Reports Q1: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
OncoCyte announces new publication on transplant rejection assay - TipRanks
Press Release Distribution & PR Platform - ACCESS Newswire
Public market insider selling at Metro (MRU) - The Globe and Mail
Oncocyte appoints new independent accounting firm - Investing.com
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - The Globe and Mail
BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias - MarketScreener
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - Defense World
OncoCyte Co. (NASDAQ:OCX) Sees Large Increase in Short Interest - Defense World
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference - TradingView
Oncocyte Unveils Game-Changing Transplant Diagnostic Technology at Major Healthcare Conference - Stock Titan
Analysts’ Recent Ratings Updates for OncoCyte (OCX) - Defense World
Oncocyte Files Secondary Stock Shelf - MarketScreener
OncoCyte (NASDAQ:OCX) Now Covered by Lake Street Capital - Armenian Reporter
Lake Street Capital Initiates Coverage on OncoCyte (NASDAQ:OCX) - Defense World
Lake Street starts OncoCyte coverage with Buy, $5 target By Investing.com - Investing.com Canada
OncoCyte a new buy at Lake Street on transplant rejection testing - MSN
OncoCyte’s Strategic Positioning and Growth Potential in Transplant Rejection Testing - TipRanks
OncoCyte initiated with a Buy at Lake Street - TipRanks
Lake Street Initiates Coverage on OncoCyte (OCX) with Buy Rating - GuruFocus
Lake Street starts OncoCyte coverage with Buy, $5 target - Investing.com India
Why Bausch + Lomb (BLCO) Shares Are Plunging Today - The Globe and Mail
OncoCyte (NASDAQ:OCX) Given Buy Rating at Needham & Company LLC - Defense World
OncoCyte (NASDAQ:OCX) Receives “Equal Weight” Rating from Stephens - Defense World
OncoCyte Corp’s Positive Earnings Call Highlights Growth - TipRanks
OncoCyte Corp (OCX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Regulatory ... - Yahoo
Earnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advances - Investing.com Australia
Needham maintains Buy on OncoCyte, steady $4.25 target - Investing.com India
OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript - Insider Monkey
Needham maintains Buy on OncoCyte, steady $4.25 target By Investing.com - Investing.com South Africa
OncoCyte Corporation (OCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):